undamentalytics Newsletter
Sign in

Coya Therapeutics, Inc. revenue

Coya Therapeutics, Inc.'s revenue was $7.9m in fiscal 2025, up 123.6% on the year before. Over the last twelve months it was $8.0m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue06,0023,5547,9468,019
Growth on the year before——−40.8%+123.6%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Coya Therapeutics, Inc. $8.0m 1793.8% —
Aclaris Therapeutics, Inc. $8.2m -51.0% -35.9%
Adagene Inc. $7.7m 7332.8% —
Apollomics Inc. $8.5m — —
Roivant Sciences Ltd. $7.5m -67.6% -46.4%
Evaxion A/s $7.5m 125.1% —

Compare with peers

Head to head: ACRS vs COYAADAG vs COYAAPLM vs COYA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Coya Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Coya Therapeutics, Inc.